The first recognition of an occupationally induced cancer is generally attributed to Sir Percivall Pott who in 1775 described scrotal cancer 1953 , there has been less than two decades between the latter's DNA double helix proposal and the concept of "oncogenes" as put forth by Huebner and Todaro in 1969. 2 The subsequent progress of molecular oncology over the past two decades can only be described as explosive.
As a result of these rapid developments, occupational medicine now must consider both epidemiological descriptive and biochemical mechanistic models of occupational carcinogenesis. There is a considerable degree of sophistication across this spectrum of understanding as some time spent delving into the fields of occupational epidemiology and chemical genotoxicity will show. As we enter our second century of DNA research (given that Friedrich Miescher discovered nuclein in 1869) and-our third century of occupational cancer epidemiology, we are finding these disciplines con The diminutive nine kilobase genome of the RSV was found to carry a single gene responsible for its ability to initiate and maintain neoplastic transformation. This sarcoma producing gene was called "src" (pronounced "sarc" for SaRC-oma) and it has become the prototype oncogene-that is, a genetic element that contributes to the neoplastic transformation of cells. In some cases an oncogene may be inserted into the cellular genome by a retrovirus using its reverse transcriptase (whence the gene has a prefix denoting its viral source, for example, "v-src").
The To distinguish the normal "socialised" cellular genes from their oncogenic or "delinquent" variants, the former became known as proto-oncogenes. Under certain conditions such as exposure to carcinogens or chromosomal translocations, protooncogenes may be changed into cellular oncogenes or c-oncs and neoplastic transformation can result.
In 1978 the v-src oncogene product, known as p60v-src ("p" denotes a protein, "60" refers to its molecular weight in kiloDaltons, and the superscript denotes the encoding gene), was found to catalyse the addition of a phosphate molecule to other cellular proteins.7 Enzymes that phosphorylate proteins are called protein kinases, and Hunter has compared these to cellular transistors that act as amplifiers and switches in the biochemical circuitry of cells.8 Rather than phosphorylating the serine or threonine amino acids of proteins, however, as was the case for other known protein kinases, p60v-src was found to add phosphate to tyrosine, the only other amino acid with a hydroxyl group. Since the normal cell contains less than 1 % of its protein phosphate bound to tyrosine, this surprising tyrosine specificity prompted a search for similar activity in other oncoproteins, and a diverse group ofprotein tyrosine kinases or PTKs are now considered members of the Src family-for example, the oncoproteins of abl, fgr, fyn, hck, lck, lyn, and yes (figure).
Oncogenes and their associated oncoproteins often have a cryptic nomenclature that is usually derived from the retroviruses or tumours in which they were first identified. For example, the "ras" oncogene was first found in RA-t S-arcoma viruses and the recently discovered "jun" oncogene was so named for its discovery in Avian Sarcoma Virus-17, the Japanese word for 17 being "JU-Nana."
The ras oncogene family is one of the most interesting models of oncogene activation in terms of occupational cancers, the three prototype members of the ras family being H-ras (Harvey ras), K-ras (Kirsten ras), and N-ras (neuroblastoma ras). Ras oncogenes appear to have an important role in carcinogen induced tumours and have been frequently found in spontaneous human and animal neoplasms. These genes all express a 189 amino acid protein of 21 kiloDalton molecular weight, p21m, which is attached at its C-terminus to the inner side of the cell membrane. Although lacking protein kinase activity, p21 ras appears to act also as a Extra cellular Location of oncogene products. molecular switch in signal transduction by avidly binding GTP ("on" state) or GDP ("off" state).9 As p21l' cycles between its active and inactive states through its intrinsic GTPase activity, it sends an intracellular signal into the cell, possibly via the phosphatidylinositol pathway.
Ras proteins are the first oncoproteins in which crystal structures have been determined. The resulting high resolution three dimensional conformation has shown atomic interactions in the single guanine nucleotide pocket ofp2 1 rs where the well established oncogenic point mutations at amino acids 12, 13, and 61 are found.'" These mutations do not significantly affect Ras GTP/GDP binding but they decrease the p21ras GTPase activity. Hydrolysis of p2Iras bound GTP is normally accelerated more than 100-fold by a GTPase activating protein called GAP which interacts with an effector loop containing amino acids 32 to 40 in p21ras GTP. A phosphate binding loop of amino acids 8 to 15 binds the guanine nucleotide's / phosphate and has been found to be wider in the transforming p2l" which may explain the diminished GTPase activity in the oncogenic Ras."
Experimentally, nitrosomethylurea induced mammary cancer in rats produces a consistent G to A transition at the second nucleotide ofthe H-ras codon 12 (where GGA normally encodes glycine) whereas dimethylbenz(a)anthracene mutates the two adenine residues ofthe H-ras codon 61 (where CAA normally encodes glutamine). Ras oncogenes may thus provide several mutational "hot spots" for chemical carcinogens that result in constitutively activated Ras oncoproteins and unregulated oncogenic signalling as noted above.
Ras proteins represent only a subset of the greater than 20 small GTP binding proteins that include the heterotrimeric G proteins that bind GTP on their a subunit. Human pituitary tumours have been found to contain point mutations of the stimulatory G protein a chain, G,,, causing constitutive activation with on regulation of an adenylyl cyclase pathway resulting in increased synthesis ofcyclic AMP. 2 Like Ras mutations, the GTPase activity of G, is inhibited. The putative oncogene is to be known as "gsp" (pronounced "gasp" for G, protein) and promises to be the first of a new family of oncogenes that will contribute another dimension to cellular mischief. In any case, Ras and Ras related proteins have shown that GTP binding and hydrolysis is as ubiquitous a regulatory control mechanism as protein tyrosine phosphorylation.
After the discovery of the tyrosine kinase activity ofthe Src oncoprotein, further investigations showed a family ofoncogene derived protein products having both cell surface receptors and intrinsic protein tyrosine kinase activity. These molecules are known as receptor tyrosine kinases or RTKs and include the oncogenes known as erbB-1, fms, kit, mas, met, neu, ret, ros, and trk (figure). They have a common architecture consisting of an extracellular ligand binding domain (receptor) of 500 to 850 amino acids, a transmembrane domain of 20 to 30 amino acids and an intracellular domain of 500 to 600 amino acids containing a catalytic (tyrosine kinase) site.
Such an integrated receptor catalytic structure suggests that the oncogenic potential of these molecules is due to their ability to generate a mitogenic signal. Such a signal may be produced because of (a) overexpression of RTKs resulting from oncogene dysregulation or amplification (as shown for the neu oncogene in human breast cancer), (b) mutation of the ligand binding domain so as to produce conformational activation of the catalytic site in the absence of ligand (as shown for the erbB oncoprotein), or (c) mutation of the transmembrane or cytoplasmic domain so as to activate constitutively the catalytic site (as shown for the fms oncoprotein).
The receptor domains of some oncogene derived RTKs are homologous to known receptors for growth factors or other biological messengers. For example, the erbB oncogene encodes a truncated receptor for epidermal growth factor (EGF) and the mas oncogene product contains an angiotensin receptor. We have also discovered that cells may become "turned on" by so called autocrine feedback when the cell detects its own growth factors and triggers its own transformation. Oncogenes may present the cellular switches for such a process to occur.
Within the past few years much attention has focused on the role of oncogenes and their oncoproteins in cellular gene regulation. In particular, research on the control of gene transcription and cell growth has converged on the jun oncogene and its role in nuclear signalling. '3 It appears that the discovery of jun, a "nuclear" oncogene, has many parallels to that of src, a "cytoplasmic" oncogene. Like src, jun was found to be the transforming sequence in an avian retrovirus and, like src, jun may produce sarcomas in chickens. Just as src proved to be the prototype oncogene, jun may become the prototype transcription regulating oncogene. Gene regulation is accomplished by cis acting sequences called promoters. A nucleotide sequence (5'TGACTCA3') in certain gene promoters recognises the human transcription factor family known as AP-1. AP-1 binding to DNA is essential for such promoter activity and, rather unexpectedly, one of the components of AP-1 turned out to be encoded by jun.
It has recently been determined that the Jun oncoprotein may form a homodimer (Jun-Jun) but preferentially forms a Fos-Jun heterodimer with increased binding affinity for the AP-1 DNA consensus sequence, TGACTCA. Fos and Jun oncoproteins dimerise because both carry "leucine zipper" amino acid structures (leucines at seven residue intervals) in alpha helical regions. The contact surface for DNA binding is adjacent to these zipper domains and dimerisation constrains the FosJun structure for proper attachment to DNA.
The myc oncogene family (c-, L-, and N-myc) also have leucine zipper domains and appear to be nuclear transcription factors. Of particular interest has been the activation of the proto-oncogene myc by chromosomal translocations, usually via a reciprocal t (8;14) . This has been found to occur in about 80°% of cases of Burkitt's lymphoma where during B cell differentiation, a translocation juxtaposes myc from chromosome 8 to the immunoglobulin heavy chain (IgH) locus at chromosome 14 resulting in myc activation by a "head to head" IgH/myc gene fusion. A similar chromosomal activation of the c-abl protooncogene has been noted in chronic myelogenous leukaemia where a reciprocal t(9;22) rearrangement places c-abl under the control of a gene called bcr (breakpoint cluster region) resulting in a fusion oncoprotein, p210br/c-ablI Whereas jun and fos are primary targets for cell signal transduction and act as transcriptional activators via the formation of transcription complexes such as AP-1, Jun-Fos, etc, other nuclear oncogenes have different mechanisms of gene interaction. The erbA oncoprotein up 
